Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 19;23(3):1089.
doi: 10.3390/ijms23031089.

Fat and Protein Combat Triggers Immunological Weapons of Innate and Adaptive Immune Systems to Launch Neuroinflammation in Parkinson's Disease

Affiliations
Review

Fat and Protein Combat Triggers Immunological Weapons of Innate and Adaptive Immune Systems to Launch Neuroinflammation in Parkinson's Disease

Shelby Loraine Hatton et al. Int J Mol Sci. .

Abstract

Parkinson's disease (PD) is the second-most common neurodegenerative disease in the world, affecting up to 10 million people. This disease mainly happens due to the loss of dopaminergic neurons accountable for memory and motor function. Partial glucocerebrosidase enzyme deficiency and the resultant excess accumulation of glycosphingolipids and alpha-synuclein (α-syn) aggregation have been linked to predominant risk factors that lead to neurodegeneration and memory and motor defects in PD, with known and unknown causes. An increasing body of evidence uncovers the role of several other lipids and their association with α-syn aggregation, which activates the innate and adaptive immune system and sparks brain inflammation in PD. Here, we review the emerging role of a number of lipids, i.e., triglyceride (TG), diglycerides (DG), glycerophosphoethanolamines (GPE), polyunsaturated fatty acids (PUFA), sphingolipids, gangliosides, glycerophospholipids (GPL), and cholesterols, and their connection with α-syn aggregation as well as the induction of innate and adaptive immune reactions that trigger neuroinflammation in PD.

Keywords: alpha-synucleinopathy; inflammation; lipid.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The different stages and lipids that affect alpha-synuclein (α-syn) aggregation into Lewy bodies (LBs). This chart depicts the overall relationships between lipids in this paper and their effects at different stages of LBs formation, not the exact conversions of one lipid to another. Black arrows indicate lipids that aid in the pathogenesis of PD. Phosphatidic acid (PA), phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylglycerol (PG), acylphosphatidylglycerol (APG), triacylglycerols (TAGs), diacylglycerols (DAGs), docosahexaenoic acid (DHA), α-linoleic acid (α-LA), eicosapentaenoic acid (EPA), eicosatrienoic acid (ESA), arachidonic acid (ARA), sphingomyelin (SM), glucosylceramide (GluCer), gangliosides (GM), P (phosphorus).

Similar articles

Cited by

References

    1. Tysnes O.-B., Storstein A. Epidemiology of Parkinson’s disease. J. Neural Transm. 2017;124:901–905. doi: 10.1007/s00702-017-1686-y. - DOI - PubMed
    1. Marras C., Beck J.C., Bower J.H., Roberts E., Ritz B., Ross G.W., Abbott R.D., Savica R., Van den Eeden S.K., Willis A.W., et al. Prevalence of Parkinson’s disease across North America. NPJ Parkinson’s Dis. 2018;4:21. doi: 10.1038/s41531-018-0058-0. - DOI - PMC - PubMed
    1. Wakabayashi K., Tanji K., Mori F., Takahashi H. The Lewy body in Parkinson’s disease: Molecules implicated in the formation and degradation of α-synuclein aggregates. Neuropathology. 2007;27:494–506. doi: 10.1111/j.1440-1789.2007.00803.x. - DOI - PubMed
    1. Wakabayashi K., Tanji K., Odagiri S., Miki Y., Mori F., Takahashi H. The Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders. Mol. Neurobiol. 2012;47:495–508. doi: 10.1007/s12035-012-8280-y. - DOI - PubMed
    1. Chen X., Feng W., Ou R., Liu J., Yang J., Fu J., Cao B., Chen Y., Wei Q., Shang H. Evidence for Peripheral Immune Activation in Parkinson’s Disease. Front. Aging Neurosci. 2021;13 doi: 10.3389/fnagi.2021.617370. - DOI - PMC - PubMed